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Summary: Our manuscript discusses the various blood biochemical markers as 
potential predictors of disease severity and mortality in COVID-19 patients. The timely 
detection of these parameters can help in providing appropriate course of treatment and 
reducing the mortality rate in the patients. We have found an association between the 
blood biochemical markers and disease severity and mortality in COVID-19 patients. 
Serum albumin, alanine aminotransferase (ALT), Erythrocyte Sedimentation Rate 
(ESR), lymphopenia, hemoglobin, and leukocytosis can reflect the severity of the 
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Background: The outbreak of coronavirus disease 2019 (COVID-19) has been rapidly 
spreading across the globe and poses a great risk to human health. Patients with 
abnormalities in laboratory parameters are more susceptible to COVID-19. Therefore, we 
explored the association of blood biochemical parameters with severity and mortality of 
COVID-19 amongst 3695 patients across seventeen studies. 
 
Methods: We searched PubMed, Cochrane library and LitCOVID database until 
February 28, 2021. Seventeen studies were included in the meta-analysis with 3695 
COVID-19 patients. 
 
Results: The pooled analysis showed that compared to non-severe group, severe group 
was characterised by significantly elevated alanine aminotransferase (ALT) 
(standardised mean difference [SMD]: 0.65, 95% confidence interval [CI]: 0.23 to 1.06; 
p<0.001, erythrocyte sedimentation rate (ESR) (SMD: 0.55, 95%CI: 0.02 to 1.07 
p=0.004) and lymphopenia (SMD: -1.22, 95% CI: -2.15 to -0.30; p<0.01), decreased 
serum albumin (SMD: -1.60, 95% CI: -2.96 to -0.22 ; p<0.001), creatinine (SMD: 0.54, 
95% CI: 0.17 to 0.90; p<0.001), lactate dehydrogenase (LDH)(SMD: -1.54, 95% CI: -
2.27 to -0.80; p=0.002) and haemoglobin (SMD:-0.89, 95% CI: ; p<0.001). 
Additionally, in the non-survivor group, elevated lactate dehydrogenase (LDH) (SMD: 
1.54 95% CI: -2.27 to 0.80; p=0.002), decreased serum albumin (SMD: 1.08, 95% CI: 
0.75 to 1.42; p<0.001) were reported. There was no comorbidity which was found to be 
significant in the severe group. 
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Conclusion: Serum albumin, ALT, ESR, lymphopenia, haemoglobin, and leucocytosis 
can reflect the severity of COVID-19, while the LDH, leucocytosis and albumin can be 
considered as risk factor to higher mortality.  
 





Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was reported in 
Wuhan (China), in December 2019. The number of cases and the associated mortality 
has increased dramatically (1). SARS-CoV-2 causes respiratory infections and is like 
Severe Acute Respiratory Syndrome Virus (SARS-CoV) (genome sequence-80 –90 per 
cent similar) and Middle East Respiratory Syndrome Virus (MERS-CoV) in terms of 
clinical symptoms. As per WHO (World Health Organisation) Coronavirus Update 
Report of  February 14, 2021, there have been 108, 153, 741 confirmed cases of 
COVID-19 and 2, 381, 295 deaths worldwide (2). 
The clinical spectrum of COVID-19 ranges from mild to severe form of the disease (3). 
Mild symptoms include fever, cough followed by sputum production, and fatigue; while 
severe symptoms include acute respiratory distress (ARDS) syndrome, and acute 
cardiac injury along with multiple organ failure (4). 
There are various laboratory parameters such as lymphocytes, leukocytes, haemoglobin, 
liver enzymes, albumin, inflammatory markers and procalcitonin that are found to be 
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deranged during the SARS-CoV-2 infection (5,6). As per previous literature, liver 
enzymes such as ALT, AST and bilirubin are found to be elevated in severe form of the 
illness due to possible liver dysfunction by the virus (1,4,7). Albumin levels have been 
found to decrease in severe illness (8–10). The inflammatory markers such as C-reactive 
protein were also found to be elevated in cases of severe infection (11). Procalcitonin, 
which is found to be elevated in bacterial infections (12) was found to be in the normal 
range in SARS-CoV-2 infection. As the production of procalcitonin increases during 
bacterial infection (13), there is simultaneous increased levels of IL-1β, tumour necrosis 
factor (TNF) and IL-6, but in case of viral infections these are inhibited by interferon-γ 
release. Thus, it can be postulated that procalcitonin will only increase if there is a 
bacterial co-infection in the patient along with COVID -19 otherwise it will be within 
the range (12). Creatinine is primarily excreted by the kidneys and abnormally high 
levels of creatinine  is an indication of  renal insufficiency which is a common 
complication in  COVID-19 patients (14).  
Several comorbidities such as hypertension, diabetes, chronic heart disease (CHD), 
chronic kidney disease (CKD) and chronic obstructive pulmonary disorder (COPD) are 
known to be prevalent in the severe group (15–17). However, more evidence needs to 
be gathered about their individual prevalence. There are various complications such as 
ARDS, pneumonia, kidney injury, septic shock as well as secondary infections which 
are also known to be related to the severe form of the illness and also related to the 
mortality of the COVID-19 patients (18,19). As the cases of COVID-19 infection are 
rapidly increasing, conduct of a comprehensive and detailed research providing better 
insights in this domain has become essential. Not only it will help in the early diagnosis 
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of the severe form of the disease but also it will help in formulating better treatment 
modalities and risk stratification in COVID-19 patients. 
Although, similar systematic reviews have been published previously (20,21). However, 
our systematic review has several merits including: a) most updated database search b) 
broader research question and, c) included additional parameters and outcomes in our 
meta-analysis which gives a detailed insight into the association of these parameters 
with disease severity and mortality in COVID-19 patients. 
Therefore, in the present meta-analysis, we aimed to understand the association between 
laboratory parameters and disease severity and mortality of COVID-19 patients. This 
will not only help broaden the horizon but also lead to the optimisation of the use of 
resources for the population at risk.  
 
2.Materials and Methods 
"Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 
guidelines for systematic reviews (22) and meta-analysis of observational studies in 
epidemiology (MOOSE) guidelines (23) were followed for designing, conduct and 
reporting this systematic literature review." The protocol of this review has been 
registered with PROSPERO (registration number CRD42020206741). 
 
  
2.1 Data sources and searches:  
We searched PubMed/Medline, Cochrane Central Register of Controlled Trials and 
Clinical Trial Registry- India until February 28, 2021 using the keywords “laboratory” 
OR “clinical”, OR “lab parameters”, “comorbidities”, “clinical outcome” AND 
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“coronavirus 2019” OR “COVID-19” OR “2019nCoV-2”, OR “SARS CoV-2”. We also 
searched grey literature using Google Scholar and reference list of eligible articles with 
the aim of identifying additional potential eligible studies.  
 
2.2 Inclusion and exclusion criteria 
Eligible studies were cross-sectional, case-control, cohort and case series reporting 
defined groups and extractable data on laboratory findings in confirmed COVID-19 
patients were included. The editorials, reviews, letters, meta-analysis, consensus and 
case reports, studies not reported in English language were excluded from the study. 
First author (AM) searched data and screened article for eligibility. Senior author (PM) 
double checked all the included articles and any dispute was resolved by consensus. 
 
2.3 Quality assessment 
Two reviewers (AM and PM) assessed the quality of data in the included studies using 
the National Institute of Health (NIH) quality assessment tools (24). We preferred the 
NIH tool because it is comprehensive and widely accepted for an exhaustive assessment 
of data quality. We rated the overall quality of included studies as good, fair and poor, 
and incorporated them in the meta-analysis results. 
 
2.4  Data extraction 
Data were inputted into a standardized data extraction table (Excel) and independently 
checked by a second reviewer (PM) for accuracy. The following variables were 
extracted: name of the first author, year of publication, study design, gender, age, 
number of patients in severe and non-severe groups, days of hospitalization along with 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted September 21, 2021. ; https://doi.org/10.1101/2021.09.16.21263675doi: medRxiv preprint 
8 
 
comorbidities of all the patients and clinical outcomes in terms of death and discharge. If 
not mentioned, the mean and standard deviation were extrapolated by median, sample 
size and interquartile range (IQR) (25). The severity of disease was defined according to 
Diagnosis and Treatment Plan of COVID-19 issued by National Health Commission, 
China (7th edition) as mild, common, severe, and critical based on the clinical symptoms 
(26). 
 
2.5 Data synthesis 
We performed an exploratory meta-analysis to understand the magnitude and direction 
of effect estimate. Continuous outcomes are presented using standardised mean 
difference (SMD) due to substantial variability in study designs and 95% confidence 
intervals (CIs). We interpreted the effect size using Cohen rule of thumb with SMD 
greater than or equal to 0.2 representing a small effect, SMD greater than or equal to 0.5 
a moderate effect, and SMD greater than or equal to 0.8 a large 
Effect (27) For dichotomous outcomes, risk ratios (RRs) were calculated and presented 
with respective 95% CIs. Mantel-Haenszel random-effects meta-analysis using 
DerSimonian and Laird method was used to pool ORs (28). Heterogeneity between 
studies was assessed using the χ2-based Cochran's Q statistic (p<0.1 considered as the 
presence of heterogeneity) and I-squared (I2) statistics (>50% representing moderate 
heterogeneity) (28). If any cell value was zero, then we added 0.5 to each cell to 
calculate risk ratio (29). Publication bias was not assessed as a total number of studies 
were less than ten in primary lab outcomes (28).  
 
3. Results 
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The systematic search yielded a total of 792 publications. Out of 792 articles, 225 were 
found using search terms “laboratory findings and COVID-19”, 108 articles were found 
using the keywords “laboratory parameters and COVID -19”, 120 studies were found 
using the keywords “comorbidities and COVID-19”. After removing duplicates, out of 
453 studies, 110 articles were excluded because they were review articles (n=30), did 
not report data on COVID-19 disease (n=36), did not provide laboratory data on 
COVID-19 patients with or without severe or without the proper categorization of the 
patients (n=34), or were editorial material (n=6) and 4 articles were excluded as they 
were in Chinese full text and could not be translated into English. Five additional 
studies were identified from the reference list of selected articles. All studies reported 
laboratory values measured at admission or earliest time point on hospitalization. 
Except for one study in which the classification of disease severity was unclear and 
hence it was not included in the meta-analysis. Thus, the meta- analysis included 17 
studies meeting the inclusion criteria (Figure 1).  
 
3.1 Study Characteristics 
All the included studies were found to be conducted in China. Out of 17 included 
studies, 11 studies reported data in severe and non-severe groups, 6 studies reported 
data in terms of patient’s survival with survivor and non-survivor groups. Among the 
seventeen included studies, five were cross-sectional studies (4,30–33), four were 
cohort studies (34) while two were case-series. The included studies enrolled a total of 
3695 patients, including 1884 males and 1811 females. The baseline characteristics of 
the subjects included in these studies are provided in Table-1. 
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The laboratory parameters of patients were taken into consideration along with the 
major comorbidities such as hypertension, diabetes, CHD, CRD. Complications in the 
patient’s post-treatment such as shock, acute respiratory distress syndrome (ARDS), 
kidney disease as well as secondary infections were also assessed. 
 
3.2 Quality Assessment 
We assessed the quality of data included in the studies using the NIH quality assessment 
tools. The quality assessment indicated that most included studies were of acceptable 
quality. All the studies clearly stated the research question or objective, the study 
population was clearly defined, and all subjects were selected from the same or similar 
population. The detailed result of the quality assessment is provided in Supplementary 
File. 
 
3.3 Laboratory Findings 
Regarding the laboratory findings, the parameters that were significantly elevated in the 
severe group were ALT (p<0.001) and ESR (p<0.001), while the albumin (p<0.001), 
haemoglobin (p<0.001) and leukocyte count (leucopoenia) (p<0.001) were found 
significantly decreased in the severe group as compared to the non-severe group. 
However, no significant difference was found in other parameters such as creatinine, 
procalcitonin, AST, C-reactive protein, lymphocyte count and LDH. Levels of LDH, 
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The prevalence of Hypertension (p=0.005) and Chronic Heart Disease (CHD) (p=0.001) 
and Chronic Obstructive Pulmonary Syndrome (COPD) (p=0.001) was found 
significantly higher in the severe group while there was no significant difference in the 
prevalence of Diabetes, Chronic Renal Disease (CRD) in the two groups. None of the 
above-mentioned comorbidities was related to the mortality of the patient (Table 3). 
 
3.5 Complications 
Out of the several complications studied, pneumonia (p=0.02) was the only significant 
complication in the severe group while there was no significant difference found in 
complications such as shock, ARDS, kidney injury and secondary infection between the 
two groups. None of the above-mentioned complications was associated with mortality 
of the patient (Table 3). 
 
3.6 Clinical Outcome 
The rate of hospitalisation (p=0.022) was more in the severe group while there was no 
significant difference in the death and discharge rates among the two groups (Table 3). 
 
4.  Discussion 
Over the last one year, more than 111,762,965 cases of COVID-19 have been confirmed 
in China and other countries in Asia, Pacific, Europe, Africa, and the America. Clinical 
and laboratory, and factors associated with evolution of the disease and outcomes, 
constitute critical knowledge that should be cautiously studied when a new infectious 
disease arises. COVID-19 has a wide spectrum of disease severity ranging from 
asymptomatic to symptomatic, mild to severe and critical nature of the illness (35). In 
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this meta-analysis, we aimed to assess the association between the laboratory 
parameters along with comorbidities and complications with disease severity and 
mortality in 3695 COVID-19 patients. (36). The laboratory parameters that were 
observed in this meta-analysis were the elevated ALT and ESR while decreased levels 
of albumin and haemoglobin were noted. However, the levels of other parameters such 
as bilirubin, LDH, CRP, AST, lymphocyte count, leucocyte count and procalcitonin 
were not found significantly different in the two groups. Data from the 2002-2003 
outbreak indicate that SARS may be associated with lymphopenia, leukopenia, and, 
elevated levels of Lactate Dehydrogenase (LDH), Alanine transaminase (ALT), Amino 
Aspartate Transaminase (AST), and creatine kinase (37,38) but they are not 
significantly seen, nor consistently reported, in COVID-19 studies and cases. The 
mortality was found to be associated with the LDH, albumin, leukopenia and 
leucocytosis across two studies (32,39). 
As per previous studies, hypertension and diabetes have been reported to be the most 
prevalent comorbidities found in COVID-19 patients. In a study in China, out of 13 
patients, hypertension was found in 5 (27.8%) and diabetes was found in 3 (16.7%) 
(16,40,41). In contrary to this, hypertension was the most prevalent comorbidity 
observed in the severe group while there was no significant difference in the prevalence 
of diabetes, CHD, CRD, and COPD between the two groups. None of the above-
mentioned comorbidity had an association with the mortality of the patient. 
Complications that were commonly observed in the severe group was pneumonia while 
the occurrence of shock, kidney injury, ARDS and secondary infections were similar in 
the two groups and only ARDS and kidney injury were related to the mortality of the 
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patients. The rate of hospitalisation was more in the severe group while there was no 
significant difference found in the rates of death and discharge between the two groups. 
Our results showed a deviation from the usual findings due to heterogeneity between the 
individual studies and small number of studies included in the meta-analysis. Thus, a 
more comprehensive analysis with a larger sample size needs to be done so that we can 
have a clear picture of the correlation of laboratory abnormalities and clinical 
parameters with the severity of the disease. More such studies are required to elucidate 
the risk factors for disease severity and death. 
There are several limitations that needs to be mentioned. There was heterogeneity 
amongst individual studies because of which there was a deviation of some of our 
results from usual findings. Additionally, case-series were included in the present meta-
analysis. Although we did an extensive search, we may have inadvertently missed 
relevant studies. Exclusion of studies in languages other than English (ie. Chinese) may 
have resulted in missing of relevant studies. Certain parameters such as IL-6 ad IL-10 
which are strong indicators of cytokine storm were not included in this meta-analysis 
due to lack of available data as not all parameters were reported in each patient. As most 
of the articles were published in Chinese, findings should interpret with caution, thereby 




COVID-19 has a wide spectrum of severity. The detection of these laboratory as well as 
clinical parameters can assist in the timely diagnosis of such patients. They can be 
associated with disease severity and mortality along with deciding the course of action 
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for COVID-19 positive patients and reducing the mortality rates in the patients. The 
patients of liver dysfunction with abnormal levels of liver enzymes and comorbidities 
such as hypertension are more prone to severe form of COVID-19 infection and 
therefore, special attention should be given to such patients. However, more such 
studies with a greater sample size needs to be conducted to get a better insight into the 
role of liver enzymes in the prognosis of COVID-19.  
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Fig.1 Flow diagram of the number of studies screened and included in the meta-analysis.
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Table 1: Baseline characteristics of the subjects 
 



















     
Male 





Total  21 17 56 7 5 3 NA NA NA 
   
Severe 11 10 61 5 4 2 NA NA NA    





Total 1099 640 47 261 165 81 27 8 12 
   
Severe 173 100 52 67 41 28 10 3 6    





Total  339 166 69 60.7 138 54 53 13 21 
   
Survivors 274 127 68 NA 106 43 32 9 10    





Total 41 30 49 13 6 8 6 NA 1 
   
Severe 13 11 49 5 2 1 3 NA 1    
Non-severe 28 19 49 8 4 7 3 NA 0 (0) 
Wang et 
al  
2020 Case Series Total  138 75 56 64 43 14 20 4 4 
   
Severe 36 22 66 26 21 8 9 2 3    
Non-severe 102 53 51 38 22 6 11 2 1 
Qin et al  2020 Cohort Study Total  452 235 58 201 135 75 27 10 12    
Severe 286 155 53 NA 105 53 24 6 9    
Non -Severe 166 80 61 NA 30 22 3 4 3 
Rong et 
al  
2020 Case Series Total 30 16 50.5  NA NA NA NA NA NA 
   
Severe 3 NA 60 NA NA NA NA NA NA 
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Total  140 71 57 90 42 17 7 NA 2 
   
Severe 58 25 64 46 22 8 4 NA 2    
Non-Severe 82 44 51.5 44 20 9 3 NA 0 
Zhou et 
al  
2020 Cohort Study Total  191 119 56 91 58 36 15 2 6 
   
Survivors 137 81 52 55 32 19 2 0 2    
Non-Survivors 54 38 69 36 26 17 13 2 4 
Hongmei 
et al 
2020 Cohort Study Total  86 38 41 16.3 7 4.7 NA 1.2 1.2 
   
Severe 44 23 42.5 18.2 11.4 6.8 NA 0 0    





Total  51 27 58.9 33 41.2 21.6 12 2 8 
   
Severe 20 8 60.0 17 65 20 9 0 4    
Non-severe 31 19 58.3 16 25.8 22.6 3 2 4 
Hao et al  2020 Retrospective 
Study  
Total  59 29 64 
 
42 9 26 NA 2 
   
ICU 44 23 66.5 
 
20 6 23 NA 1    
Non-ICU 15 6 56 
 





Total  113 71 62.5  43.9 43.9 18.4 35 NA 12 
   
Survivors 11 7 57.5  41 44.6 19.6 14 NA 3    
Non-survivors 102 64 65.7 64 43.5 17.7 21 NA 9 
Buckner 
et al  
2020 Retrospective 
Study  
Total  105 53 69 NA 59 33 38 26 10 
   
Severe 51 30 70 NA 59 35 35 29 14    
Non-severe 54 23 67 NA 59 31 42 22 7 
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Cao et al  2020 Cohort Study  Total 80 38 53 NA 20 6 10 NA 5    
Severe 27 16 71 NA 4 0 5 NA 0    
Non-Severe 53 22 44 NA 16 6 5 NA 5 
Li et al 2020 Retrospective 
Study  
Total  312 187 69.2  NA 57.1 38.8 29.8 3.21 NA 
   
Severe 105 67 71.3 NA 82.9 46.7 43.8 3.81 NA    





Total  135 72 47 31.9 9.6 8.9 5.2 NA 0 
   
Severe 40 21 56 70 10 22.5 15 NA 4    
Non-Severe 95 52 44 16.3 9.4 3.1 1 NA 0 
Data is presented as Median (IQR) or number (%). 
No.-number. NA-not available. IQR-inter quartile range. COPD-Chronic Obstructive Pulmonary Syndrome. CHD-Chronic Heart Disease. CRD-Chronic Renal 
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Severe vs Non-severe Survivors vs Non- survivors 
No. of Studies 
(patients) 
 
Effect size (95% CI) 
p - 
value 
I2 No. of Studies 
(patients) 
 

























10 (494) 1.19 (0.40 to 1.98) p<0.001 96.0 
% 
2 (452) -1.84 (-3.91 to 0.23) p<0.001 97.0% 
LDH 7 (240) 1.48 (0.48 to 2.49) p<0.001 97.1% 2 (530) -1.54 (-2.27 to -0.80) 0.002 89.9% 
Albumin 5 (279) -1.59 (-2.96 to -0.22) p<0.001 95.5% 1 (191) 1.08 (0.75 to 1.42) p<0.001 “-“% 
Bilirubin 9 (969) 0.47 (0.09 to 0.85) p<0.001 85.4% 1 (113) -0.80 (-1.43 to -0.17) p<0.001 “-“% 
C- reactive 
Protein 
8 (944) 1.02 (-0.95 to 2.983) p<0.001 96.5% 1 (339) -0.92 (-1.20 to -0.64) p<0.001 “-“% 
Creatinine 10 (494) 0.53 (0.17 to 0.90) p<0.001 84.9 
% 
2 (530) -0.35 (-0.56 to -0.15) 0.973 0.0 % 
Hemoglobin 8 (944) -0.90 (-1.43 to -0.34) p<0.001 94.0 
% 
2 (452) -0.20 (-0.45 to 0.04) 0.489 0.0 % 
Leucopenia  12 (2668) 1.10 (0.46 to 1.74) p<0.001 97.5 
% 
3 (643) -1.02 (-1.33 to -0.72) 0.154 46.6 
% 
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Lymphopenia 13 (2698) -1.22 (-2.14 to -0.30) p<0.001 98.7 
% 
3 (643) 1.72 (-0.61 to 4.07) p<0.001 98.7 
% 
Procalcitonin 8 (944) 0.66 (0.13 to 1.19) p<0.001 98.6 
% 
1 (339) -0.46 (-0.74 to -0.19) - - 
ESR 3 (589) 0.54 (0.02 to 1.07) 0.004 82.0 
% 
-  -  -  -  
 
SMD-Standard mean difference as follows: Severe vs. Non-severe; Non-survivors vs. survivor patients. CI-Confidence Interval. CRP-
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Table 3: Results of meta-analysis comparing co-morbidities, complications, and clinical outcome in COVID-19 patients with and 




No. of Studies (subjects) RR (95%CI) p - value I2 
Hypertension  13 (2660) 1.28 (1.08 to 1.53) 0.005 52.0 % 
Diabetes 16 (2828) 1.25 (1.04 to 1.52) 0.018 64.2 % 
CHD 11 (2612) 1.43 (1.16 to 1.77) 0.001 57.5 % 
CRD 7 (2243) 1.26 (0.97 to 1.65) 0.083 0.0% 
COPD 11 (2612) 1.85 (1.30 to 2.61) 0.001 68.6 % 
Shock  3 (1278) 1.12 (0.91 to 1.38) 0.297 0.0% 
ARDS 3 (1278) 2.02 (0.91 to 4.48) 0.082 74.7% 
Kidney Injury 3 (1278) 1.04 (0.85 to 1.29) 0.675 0.0% 
Pneumonia 1 (1099) 23.54 (3.27 to 169.54) 0.002 .% 
Secondary Infection 1 (41) 1.44 (0.53 to 3.92) 0.470 .% 
Discharge 2 (1140) 0.96 (0.76 to 1.201) 0.699 0.0% 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 





RR-Relative Risk: Severe vs Non-severe; Non-survivor vs survivor patients. NA-Not Applicable. CI-Confidence interval. NA-not 
available. CHD-Chronic Heart Disease. CRD-Chronic Renal Disease. COPD-Chronic Obstructive Pulmonary Syndrome. ARDS-
Acute respiratory distress syndrome
Death 2 (1140) 1.11 (0.88 to 1.390) 0.384 0.0% 
Hospitalization 2 (1140) 0.57 (0.35 to 0.92) 0.022 0.0% 
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Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for 
Scoping Reviews (PRISMA-ScR) Checklist 
SECTION ITEM PRISMA-ScR CHECKLIST ITEM 
REPORTED 
ON PAGE # 
TITLE 





Provide a structured summary that includes (as 
applicable): background, objectives, eligibility criteria, 
sources of evidence, charting methods, results, and 





Describe the rationale for the review in the context of 
what is already known. Explain why the review 




Provide an explicit statement of the questions and 
objectives being addressed with reference to their key 
elements (e.g., population or participants, concepts, 
and context) or other relevant key elements used to 






Indicate whether a review protocol exists; state if and 
where it can be accessed (e.g., a Web address); and if 
available, provide registration information, including 
the registration number. 
- 
Eligibility criteria 6 
Specify characteristics of the sources of evidence 
used as eligibility criteria (e.g., years considered, 






Describe all information sources in the search (e.g., 
databases with dates of coverage and contact with 
authors to identify additional sources), as well as the 
date the most recent search was executed. 
7 
Search 8 
Present the full electronic search strategy for at least 1 







State the process for selecting sources of evidence 






Describe the methods of charting data from the 
included sources of evidence (e.g., calibrated forms or 
forms that have been tested by the team before their 
use, and whether data charting was done 
independently or in duplicate) and any processes for 
obtaining and confirming data from investigators. 
8 
Data items 11 
List and define all variables for which data were 
sought and any assumptions and simplifications made. 
8 




If done, provide a rationale for conducting a critical 
appraisal of included sources of evidence; describe 
the methods used and how this information was used 
in any data synthesis (if appropriate). 
- 
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SECTION ITEM PRISMA-ScR CHECKLIST ITEM 
REPORTED 




Describe the methods of handling and summarizing 







Give numbers of sources of evidence screened, 
assessed for eligibility, and included in the review, with 







For each source of evidence, present characteristics 
for which data were charted and provide the citations. 
9 
Critical appraisal 
within sources of 
evidence 
16 
If done, present data on critical appraisal of included 






For each included source of evidence, present the 
relevant data that were charted that relate to the 





Summarize and/or present the charting results as they 






Summarize the main results (including an overview of 
concepts, themes, and types of evidence available), 
link to the review questions and objectives, and 
consider the relevance to key groups. 
12-13 
Limitations 20 Discuss the limitations of the scoping review process. 14 
Conclusions 21 
Provide a general interpretation of the results with 
respect to the review questions and objectives, as well 




Describe sources of funding for the included sources 
of evidence, as well as sources of funding for the 
scoping review. Describe the role of the funders of the 
scoping review. 
2 
JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses 
extension for Scoping Reviews. 
* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media 
platforms, and Web sites. 
† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., 
quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping 
review as opposed to only studies. This is not to be confused with information sources (see first footnote). 
‡ The frameworks by Arksey and O’Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the 
process of data extraction in a scoping review as data charting. 
§ The process of systematically examining research evidence to assess its validity, results, and relevance before 
using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable 
to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used 
in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document). 
 
 
From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Chec klist and 
Explanation. Ann Intern Med. 2018;169:467–473. doi: 10.7326/M18-0850. 
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